Cara Therapeutics Inc (CARA)

[king oil]

Several upcoming milestones listed in annual results:

Expected 2019 Clinical Milestones

Top-line 12-week efficacy and safety data from the KALM-1 and KALM-2 Phase 3 trials of KORSUVA™ Injection in hemodialysis patients with moderate-to-severe CKD-aP are expected in the second quarter and second half of 2019, respectively.

Top-line data from the Phase 2 trial of Oral KORSUVA™ in Stage III - V CKD patients (moderate-to-severe) CKD-aP are expected in the second half of 2019.

Initiation of the Phase 2 trial of Oral KORSUVA™ in patients with CLD-aP is expected in the second quarter of 2019.

Initiation of the Phase 2 trial of Oral KORSUVA™ in atopic dermatitis patients with moderate-to-severe pruritus is expected around mid-year 2019.